An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Lilian Zhou Appointed to STAAR Surgical Board of Directors
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) appoints Lilian Zhou, an accomplished investment portfolio manager, to its Board of Directors. Ms. Zhou brings over two decades of capital markets and investment experience to STAAR, having worked at highly regarded Wall Street investment institutions and founded her own firm. The company also announced the departure of Gil Kliman, M.D., from the board to focus on other commitments.
Positive
None.
Negative
None.
LAKE FOREST, Calif.--(BUSINESS WIRE)--
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023.
“We welcome Lilian Zhou as a new member to our Board of Directors. Lilian is an accomplished investment portfolio manager who worked at highly regarded Wall Street investment institutions before founding her own firm a decade ago,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors. "We look forward to Lilian’s contributions as a former institutional shareholder of STAAR with an in-depth and global perspective of healthcare, ophthalmology and STAAR’s opportunity."
Lilian Zhou brings more than two decades of capital markets and investment experience to STAAR. Most recently, Ms. Zhou was Founder, Chief Investment Officer and Managing Partner of Yulan Capital Management, a Tiger Seed, which operated out of New York and Shanghai from 2013 through June 2023. Prior to Yulan Capital, Ms. Zhou worked at Citadel, Kelusa Capital and Bear Stearns & Co. Lilian began her career as an investment banking analyst at Credit Suisse in 2004. Ms. Zhou is a Chartered Financial Analyst (CFA) and holds a Bachelor of Arts, Economics and Mathematics-Statistics, from Columbia University and an MBA from The Wharton School, University of Pennsylvania.
STAAR also reported today that Gil Kliman, M.D., has decided to leave the board, effective December 1, in order to more fully devote his time and energies to his other commitments. Tom Frinzi, STAAR’s Chair of the Board, stated, “STAAR has benefitted greatly from Dr. Kliman’s extensive ophthalmology, commercial and medical device experience and we sincerely thank Gil for his dedicated service. He has been a steadfast supporter of STAAR, and we hope to continue to benefit from his insights in the future.”
Other current members of STAAR’s Board of Directors include Stephen Farrell, Tom Frinzi, Aimee Weisner, Elizabeth Yeu, M.D., and K. Peony Yu, M.D.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 2,500,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.
Investors & Media
Brian Moore
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com
Source: STAAR Surgical Company
FAQ
Who is the newest member of STAAR Surgical Company's Board of Directors?
Lilian Zhou, an accomplished investment portfolio manager, is the newest member of STAAR Surgical Company's Board of Directors.
What is the ticker symbol for STAAR Surgical Company?
The ticker symbol for STAAR Surgical Company is STAA.
What is the professional background of Lilian Zhou?
Lilian Zhou brings over two decades of capital markets and investment experience to STAAR, having worked at highly regarded Wall Street investment institutions and founded her own firm.
Why did Gil Kliman, M.D., decide to leave the board of STAAR Surgical Company?
Gil Kliman, M.D., decided to leave the board in order to more fully devote his time and energies to his other commitments.
staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl". nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad